STAT+: Pharmalittle: We’re reading about a CRISPR approval, selling meds directly to patients, and more
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
Category: STAT+
STAT+: FDA clears AI skin cancer detector for primary care doctors to use
The Food and Drug Administration cleared an AI-powered device for detecting skin cancer on Wednesday,…
STAT+: More patients are getting their meds online. Big Pharma wants in on the action
Since the pandemic, patients have become increasingly comfortable with getting their medications online. Direct-to-consumer telehealth…
STAT+: Hair loss is one of the most hated chemotherapy side effects. A new biotech hopes to prevent it
The chemotherapy Christine Ko was prescribed for her breast cancer is pretty much a guarantee…
STAT+: At health care’s biggest investor conference, AI’s high hopes collided with skepticism
You didn’t need machine learning to make one prediction about the year’s biggest conference for…
STAT+: Dewpoint Therapeutics cuts 15% of staff, acknowledges Merck, Pfizer broke off partnerships over buzzy science
Dewpoint Therapeutics, the buzziest startup trying to tackle a new field of biology called biomolecular…
STAT+: FDA expands approval of CRISPR-based medicine to treat beta thalassemia
The Food and Drug Administration on Tuesday approved a CRISPR-based medicine to treat beta thalassemia,…
STAT+: Survey: Confusion over key requirements means clinical trials aren’t registered and results aren’t reported
More than half of those responsible for registering clinical trials and reporting results fail to…
STAT+: Pharmalittle: We’re reading about Wegovy shipments, the NIH director’s plans, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
STAT+: The new NIH director is walking a tightrope on Biden’s drug pricing vision
WASHINGTON — President Biden has promised to require fair prices from drugmakers that use federally…
STAT+: Many doctors are in the dark about how FDA approves devices and drugs, survey finds
In her final presentation for health policy class at the University of Chicago, first-year medical…
STAT+: Could private equity be the future of private practice? A new lobbying group thinks so
Private equity gets a bad rap in health care. But some doctors see that kind…
STAT+: Nonprofit health systems plug their strong cash reserves at JPM — a very different pitch than they make elsewhere
SAN FRANCISCO — Hospital leaders spent a good chunk of their stage time at the…
STAT+: New congressional bill would thwart patent thickets in order to speed generic drugs to market
In the latest bid to lower the cost of medicines, a new bill was introduced…
STAT+: Fiery MedPAC meeting highlights massive overpayments in Medicare Advantage
Medicare Advantage is arguably the most controversial health care program right now — a sentiment…
STAT+: Pharmalittle: We’re reading about GLP-1 drugs’ safety, Novartis nixing a deal, and more
And so, another working week will soon come to a close. Not a moment too…
STAT+: Rune Labs, which makes an app to track Parkinson’s symptoms, raises $12 million
Rune Labs, maker of an Apple Watch app that can track symptoms related to Parkinson’s…
STAT+: Pharmalittle: We’re reading about FDA’s syphillis-drug plan, India’s manufacturer-inspection demands, and more
Rise and shine, another busy day is on the way. However, this is also shaping…
.jpg)
STAT+: Courts will decide the future of Medicare’s power to negotiate drug prices within months
WASHINGTON — Pharmaceutical companies’ efforts to scuttle President Biden’s signature health care achievement, empowering Medicare…
STAT+: A biotech reporter’s notebook: Sunshine rains down on San Francisco
SAN FRANCISCO — It seemed like there was a point during last year’s J.P. Morgan…
STAT+: U.K. sequencing study surfaces new findings about tumor DNA
LONDON — A decade ago, the U.K. launched its 100,000 Genomes Project, a major research…
STAT+: At JPM, Verve details plot to take genome editing mainstream
SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines…
STAT+: Heated lawsuit between AdventHealth, MultiPlan attracts hospital lobbyists
A lawsuit between a large hospital system and a dominant vendor that works for health…
STAT+: Pharmalittle: We’re reading about Sanofi’s Olympics bet, Singulair problems, and more
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Bayer’s promising menopause drug trial results highlight growing interest in long-neglected condition
More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two…
STAT+: Morgan Health wants you to know it’s still here
SAN FRANCISCO — Almost three years ago, the country’s biggest bank unveiled a lofty plan…
STAT+: FDA’s Peter Marks seems inclined to grant full approval to Sarepta’s Duchenne gene therapy
SAN FRANCISCO — Peter Marks, the Food and Drug Administration’s top regulator of gene therapies,…
STAT+: Pharmalittle: We’re reading about a GSK deal, a probe into inhaler prices, and more
Rise and shine, everyone, another busy day is on the way. We can tell by…
STAT+: Nvidia says a biological revolution is happening now. But is it?
SAN FRANCISCO — The small hotel meeting room was packed like a rush hour subway….
STAT+: JPM 2024: FogPharma’s new CEO, Mathai Mamman, unveils ‘contrarian’ plan in oncology
SAN FRANCISCO — Six months into his tenure as CEO of cancer startup FogPharma, Mathai…
STAT+: Doudna institute hatches plan to ‘cure hundreds of diseases’ left behind by CRISPR revolution
Researchers attending gene therapy meetings over the past couple years were liable to bump into…
STAT+: HHS’s Xavier Becerra, once an ‘invisible’ secretary, is racing to cement a clearer legacy
WASHINGTON — He’s been called the “invisible” secretary. So far removed from the White House…
STAT+: GSK to acquire Aiolos Bio in $1.4 billion deal, picking up an experimental asthma drug
LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for…
.jpg)
STAT+: Mayo Clinic partners with supercomputing startup Cerebras to build custom AI tools
SAN FRANCISCO — Mayo Clinic has signed Silicon Valley tech startup Cerebras as its first…
STAT+: Hospitals try a new pitch to investors: other ways of making money
SAN FRANCISCO — If you learned anything about nonprofit hospitals on the first day of…
STAT+: Florida faces ‘complicated road’ before actually importing drugs from Canada, expert says
Last week, the Food and Drug Administration granted Florida permission to import medicines from Canada,…
STAT+: CVS Health sees Medicare Advantage patients seek more care, eating into profits
Medicare Advantage members continue to go to the doctor and get health care procedures a…
STAT+: Sen. Sanders, others lawmakers open probe into asthma inhaler makers over pricing, patent maneuvers
Several U.S. lawmakers including Sen. Bernie Sanders (I-Vt.) are investigating the prices charged by four…
STAT+: Walgreens isn’t acquiring anytime soon, per CEO
Between Walgreens’ earnings call last week and its J.P. Morgan Healthcare Conference presentation on Monday,…
STAT+: At JPM, biotech’s most prolific dealmaker sees a rosy 2024 for acquisitions
SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong…
STAT+: At JPM, Bristol’s new CEO appeals to history to try to soothe investors’ nerves
SAN FRANCISCO — Christopher Boerner has been the CEO of Bristol Myers Squibb for just two…
STAT+: Pharmalittle: We’re reading about LillyDirect, India’s drug standards, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: The ADC hot streak continues: J&J to buy cancer drug developer Ambrx Biopharma
Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion,…
STAT+: Merck to acquire Harpoon Therapeutics for $680 million
Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs…
STAT+: Former Sage executives join biotech VC Cure Ventures
Cure Ventures, a Boston-based venture capital firm founded in 2021 by a trio of veteran…
STAT+: HHS names inaugural chief competition officer
The Department of Health and Human Services will name Stacy Sanders as its new chief…
STAT+: Backed by Mayo Clinic and Microsoft, a nonprofit forms to test AI tools used in health care
A group of academic hospitals and technology companies will form a new nonprofit venture to…
STAT+: Insitro, biotech AI’s quiet unicorn, unveils efforts in ALS, liver disease, and cancer at JPM
New artificial intelligence technologies made headlines last year for their ability to do everything from…
STAT+: What to expect from hospitals and health insurers at this year’s JPM Healthcare Conference
Nonprofit hospitals often get overshadowed at the J.P. Morgan Healthcare Conference, the health care industry’s…
STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news
And so, another working week will soon come to a close. Not a moment too…